top of page

NCI-2022-03770

A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients With HER2-Expressing Advanced Solid Tumors


This is an early-stage research study that is designed to evaluate the safety, tolerability, and preliminary efficacy of an investigational drug called IMM2902. IMM2902 is a type of drug called an antibody-drug conjugate (ADC). ADCs are made up of two parts: an antibody that targets a specific protein on cancer cells and a drug that kills the cancer cells. The HER2 protein is found in high levels in many types of cancer, including breast, ovarian, and bladder cancer. IMM2902 is designed to target the HER2 protein and deliver the drug to the cancer cells. The study is open to adults with advanced solid tumors that express the HER2 protein and who have not received prior treatment with an ADC. The study will be conducted in two parts: Part 1: This is a dose-escalation phase, where researchers will determine the safest and most effective dose of IMM2902.

Part 2: This is a dose-expansion phase, where researchers will further evaluate the safety and effectiveness of IMM2902 at the chosen dose from Part 1 in a larger group of patients.


Early-stage: Early phase (phases I and II) studies help researchers determine: Whether a new treatment is safe, what its side effects are and the best dose of the new treatment.


For more information about the trial, click the link below:

NCI-2022-03770

Clinical Trial Site: Sinai


To see all available clinical trials click here.



Recent Posts

See All

NCI-2022-06272

A first-in-human, phase 1/2, open-label, multi-center, dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of the ATR inhibitor IMP9064

NCI-2019-04202

A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC. Some patients have a tumor that is “resectable,” which means that it is able to be rem

NCI-2022-05056

Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma (Phase II Study) This is a medical study to evaluate the safety and efficacy of tislelizumab in combination with ot

bottom of page